EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 29, 2015, Pages E3855-E3863

  Phuchareon, Janyaporn ^a,b   McCormick, Frank ^a,b   Eisele, David W ^a,b   Tetsu, Osamu ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

EGFr inhibition; ERK1 2 paradoxical activation; Innate drug resistance; Nonsmall cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

BETA ACTIN; BIM PROTEIN; CYCLIN D1; CYCLIN D3; CYCLIN E2; CYCLINE; DUAL SPECIFICITY PHOSPHATASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEFITINIB; LAPATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; ETS1 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; TUMOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CYCLINS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; MUTATION; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SRC-FAMILY KINASES;

EID: 84937460123     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510733112     Document Type: Article

References (50)

1. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10(11):760-774.
2. Chong CR, Jänne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19(11):1389-1400.
3. Rosell R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239-246.
4. Lippert TH, Ruoff HJ, Volm M (2011) Current status of methods to assess cancer drug resistance. Int J Med Sci 8(3):245-253.
5. Wilson TR, et al. (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487(7408):505-509.
6. Straussman R, et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487(7408):500-504.
7. Kentsis A, et al. (2012) Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med 18(7):1118-1122.
8. Nassar N, Singh K, Garcia-Diaz M (2010) Structure of the dominant negative S17N mutant of Ras. Biochemistry 49(9):1970-1974.
9. Stommel JM, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848):287-290.
10. Guo A, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105(2):692-697.
11. van der Geer P, Wiley S, Gish GD, Pawson T (1996) The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions. Curr Biol 6(11):1435-1444.
12. Weidner KM, et al. (1996) Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384(6605):173-176.
13. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ (1996) A Grb2- associated docking protein in EGF- and insulin-receptor signalling. Nature 379(6565): 560-564.
14. Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M (2000) The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signalregulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 20(22):8513-8525.
15. Tice DA, Biscardi JS, Nickles AL, Parsons SJ (1999) Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96(4):1415-1420.
16. Biscardi JS, et al. (1999) c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274(12):8335-8343.
17. Zhang J, et al. (2007) SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366-376.
18. Marcotte R, Zhou L, Kim H, Roskelly CD, Muller WJ (2009) c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential. Mol Cell Biol 29(21):5858-5871.
19. Patwardhan P, Resh MD (2010) Myristoylation and membrane binding regulate c-Src stability and kinase activity. Mol Cell Biol 30(17):4094-4107.
20. Aleshin A, Finn RS (2010) SRC: A century of science brought to the clinic. Neoplasia 12(8):599-607.
21. Batzer AG, Rotin D, Ureña JM, Skolnik EY, Schlessinger J (1994) Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 14(8): 5192-5201.
22. Donepudi M, Resh MD (2008) c-Src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling. Cell Signal 20(7):1359-1367.
23. Caunt CJ, Keyse SM (2013) Dual-specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling. FEBS J 280(2):489-504.
24. Tetsu O, McCormick F (2003) Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3(3):233-245.
25. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398(6726):422-426.
26. Yang BS, et al. (1996) Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol 16(2):538-547.
27. Slupsky CM, et al. (1998) Structure of the Ets-1 pointed domain and mitogen-activated protein kinase phosphorylation site. Proc Natl Acad Sci USA 95(21):12129-12134.
28. Ekerot M, et al. (2008) Negative-feedback regulation of FGF signalling by DUSP6/ MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem J 412(2):287-298.
29. Zhang Z, et al. (2010) Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31(4):577-586.
30. Kohn AD, Takeuchi F, Roth RA (1996) Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem 271(36):21920-21926.
31. Costa DB, et al. (2007) BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4(10):1669-1679, discussion 1680.
32. Luciano F, et al. (2003) Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22(43):6785-6793.
33. Ewings KE, et al. (2007) ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 26(12):2856-2867.
34. Zimmermann S, Moelling K (1999) Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286(5445):1741-1744.
35. Solit DB, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439(7074):358-362.
36. Joseph EW, et al. (2010) The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 107(33): 14903-14908.
37. Zhao Y, Adjei AA (2014) The clinical development of MEK inhibitors. Nat Rev Clin Oncol 11(7):385-400.
38. Oka T, Rairkar A, Chen JH (1991) Structural and functional analysis of the regulatory sequences of the ets-1 gene. Oncogene 6(11):2077-2083.
39. Majérus MA, Bibollet-Ruche F, Telliez JB, Wasylyk B, Bailleul B (1992) Serum, AP-1 and Ets-1 stimulate the human ets-1 promoter. Nucleic Acids Res 20(11):2699-2703.
40. Chen Z, et al. (1997) Elevated expression of ETS-1 gene in a metastatic, tumorigenic human prostate epithelial cell line transformed by the v-Ki-ras oncogene. Int J Oncol 11(6):1179-1184.
41. Smith AM, et al. (2012) ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype. Carcinogenesis 33(3):572-580.
42. Tootle TL, Rebay I (2005) Post-translational modifications influence transcription factor activity: A view from the ETS superfamily. BioEssays 27(3):285-298.
43. Smith JL, et al. (2000) ets-2 is a target for an akt (Protein kinase B)/jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice. Mol Cell Biol 20(21):8026-8034.
44. Rieske P, Pongubala JM (2001) AKT induces transcriptional activity of PU.1 through phosphorylation-mediated modifications within its transactivation domain. J Biol Chem 276(11):8460-8468.
45. Obenauer JC, Cantley LC, Yaffe MB (2003) Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31(13): 3635-3641.
46. Yang C, Shapiro LH, Rivera M, Kumar A, Brindle PK (1998) A role for CREB binding protein and p300 transcriptional coactivators in Ets-1 transactivation functions. Mol Cell Biol 18(4):2218-2229.
47. Huang WC, Chen CC (2005) Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol 25(15):6592-6602.
48. de Launoit Y, Audette M, Pelczar H, Plaza S, Baert JL (1998) The transcription of the intercellular adhesion molecule-1 is regulated by Ets transcription factors. Oncogene 16(16):2065-2073.
49. Yockell-Lelièvre J, et al. (2009) Functional cooperation between Stat-1 and ets-1 to optimize icam-1 gene transcription. Biochem Cell Biol 87(6):905-918.
50. Tetsu O, et al. (2010) Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia 12(9):708-717.